Collegium Pharmaceutical is packing up its headquarters in Stoughton and heading straight for Boston’s Financial District, staking out a big new footprint at One Lincoln. The company said Monday it will take roughly 40,000 square feet across two full floors of the tower, in a move local reporting notes will make Collegium the building’s first biotech tenant.
According to the Boston Business Journal, President and CEO Vikram Karnani pointed to Greater Boston’s deep talent pool as a central reason for the relocation. The outlet reported that the shift downtown is aimed at giving Collegium a more visible urban presence while making daily commutes and transit connections easier for staff.
Lease Details and One Lincoln's Repositioning
Landlord DivcoWest said in a press release that Collegium has signed on for 40,288 square feet spanning the 11th and 12th floors of One Lincoln, the 36‑story tower that completed a major repositioning in 2025. The firm highlighted the building’s expanded amenities and its proximity to South Station as key draws, and it named Avison Young and Newmark as the brokers who put the deal together. With Collegium on board, the tower adds a life‑science foothold to a tenant list that has traditionally leaned toward finance and professional services.
What the Move Signals for Downtown Biotech
The relocation reflects a broader trend of life‑science companies weighing downtown perks, transit access and branded office space alongside the pull of suburban lab clusters. In a company statement, Collegium Pharmaceutical described the headquarters move as a long‑term commitment to Massachusetts and said the new Boston base is intended to better support collaboration as the business scales up.
Next Steps
Collegium expects to complete the relocation in the first quarter of 2027, according to the initial announcement, with tenant fit‑out work scheduled ahead of the staff transition. The company plans to maintain operations in Stoughton while it gradually shifts corporate functions into the downtown space.
